ARICEPT ODT Drug Patent Profile

When do Aricept Odt patents expire, and what generic alternatives are available?

Aricept Odt is a drug marketed by Eisai Inc and is included in one NDA.

The generic ingredient in ARICEPT ODT is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aricept Odt

A generic version of ARICEPT ODT was approved as donepezil hydrochloride by AUROBINDO on May 31^st, 2011.

Summary for ARICEPT ODT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	152
Patent Applications:	4,785
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARICEPT ODT
DailyMed Link:	ARICEPT ODT at DailyMed

Recent Clinical Trials for ARICEPT ODT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Virginia	PHASE2
Changchun University of Chinese Medicine	EARLY_PHASE1
Vanderbilt University Medical Center	Early Phase 1

See all ARICEPT ODT clinical trials

Paragraph IV (Patent) Challenges for ARICEPT ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARICEPT ODT	Orally Disintegrating Tablets	donepezil hydrochloride	5 mg and 10 mg	021720	1	2010-06-30

US Patents and Regulatory Information for ARICEPT ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-001	Oct 18, 2004		DISCN	Yes	No
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-002	Oct 18, 2004		DISCN	Yes	No

Expired US Patents for ARICEPT ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-001	Oct 18, 2004
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-001	Oct 18, 2004
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-002	Oct 18, 2004

International Patents for ARICEPT ODT

See the table below for patents covering ARICEPT ODT around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	T50768
China	1034015
Japan	3770518

Supplementary Protection Certificates for ARICEPT ODT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
0296560	98C0015	Belgium		PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21 303 19980415; FIRST REGISTRATION: GB - 10592/0078 19960228

ARICEPT ODT (donepezil hydrochloride) Market Dynamics and Financial Trajectory

Last updated: April 29, 2026

What is ARICEPT ODT and how is it positioned in the market?

ARICEPT ODT is the orally disintegrating tablet (ODT) formulation of donepezil hydrochloride, used in Alzheimer’s disease. In commercial terms, the product competes in a mature, branded dementia category where growth is limited by diagnosis rates, aging demographics, payer access, and the extent to which competitors offer oral-dosing convenience or formulary preference.

The ODT format is a convenience-led variant of donepezil rather than a new pharmacologic mechanism. Market positioning therefore hinges on:

• Dosing accessibility (patients who have trouble swallowing)
• Formulary management (switching within donepezil branded and generic structures)
• Lifecycle dynamics (ODT is a differentiation strategy inside a class with long patent/composition timelines)

Where does ARICEPT ODT sit within the competitive landscape?

ARICEPT ODT is part of a broader donepezil market that includes:

• Branded donepezil products (multiple formulations exist historically across ARICEPT)
• Generic donepezil hydrochloride tablets (lower-cost alternatives)
• Other Alzheimer’s symptomatic agents (different mechanisms, different payer usage patterns, and different line-of-therapy placement)

In practice, the ODT segment’s competitive edge is convenience. Payers typically price and tier ODT based on incremental value versus generic tablets. That drives the product’s financial trajectory, especially after generic penetration in the donepezil class.

How do pricing and payer dynamics typically shape revenues for ARICEPT ODT?

Revenue performance in this market tends to be determined by:

• Net price compression due to generic substitution pressure
• Formulary access (preferred vs non-preferred status)
• Patient persistence in chronic symptomatic use
• Switch rates within the same molecule (tablet vs ODT, branded vs generic)

ODT products commonly see:

• Higher list prices than generic tablets
• Greater payer review for step therapy or prior authorization in later years
• Lower elasticity in the target subgroup (patients with dysphagia or adherence constraints), but limited addressable population overall

What market dynamics are most likely to influence demand?

The Alzheimer’s symptomatic market is structural and driven by macro and clinical system factors:

• Diagnosed prevalence of Alzheimer’s (supply of diagnosed patients)
• Stage distribution (ODT convenience can matter more where swallowing is difficult)
• Adherence and discontinuation rates (chronic dosing affects realized net sales)
• Managed care formularies (especially where generic donepezil is available)

Because ARICEPT ODT is a formulation variant, demand shifts usually come from:

• Patient-level switching from tablets to ODT within donepezil
• Payer-level switching from ODT to generic tablets when cost pressure rises
• Channel-level shifts (retail pharmacy vs mail order), which affects timing of uptake after formulary actions

What do regulatory and patent timelines imply for financial trajectory?

The regulatory anchor is donepezil’s long-standing approval and subsequent generic availability. For formulation-level ODT products, the financial trajectory usually follows a pattern:

1. Launch or expansion period with higher uptake on convenience-led differentiation
2. Gradual normalization as payers steer toward lower-cost donepezil
3. Sustained but pressured sales where ODT maintains a portion of the market for patients who cannot tolerate tablets

Key signals come from the drug’s established regulatory footprint and the broader authorization and genericization of donepezil.

What financial trajectory pattern is typical for ARICEPT ODT-like products?

For an ODT formulation of a long-mature molecule, revenue tends to show:

• Peak-to-decline after generic substitution consolidates payer choice
• Residual growth or stabilization only if ODT formulary access remains favorable or if patient-switching persists faster than payer cost tightening
• Volatility around formulary decisions, especially in Medicare Part D and large PBM networks

What measurable data supports ARICEPT ODT’s presence in the market?

ARICEPT ODT is listed as a branded donepezil ODT product in standard U.S. drug directories and reference databases, which confirms its commercial identity and availability:

• FDA’s Orange Book catalogs the reference listed drug and associated patents, supporting the regulatory basis for market entry and exclusivity status. (FDA Orange Book) [1]
• FDA labeling and drug reference sources document the dosage form and approved indication context. (FDA Labeling via DailyMed) [2]

What is the likely revenue inflection from generic competition?

The donepezil class includes extensive generic availability, which shifts economics from branded differentiation to cost competitiveness. For ARICEPT ODT, the economic effect typically manifests as:

• Lower than molecule-class market growth
• Margin compression through rebates and formulary pricing pressure
• Reduced share over time as generic tablets become the default payer choice

This creates a financial trajectory where ARICEPT ODT persists, but growth is capped by:

• the rate at which generic substitution penetrates remaining non-preferred channels, and
• the proportion of patients for whom ODT is clinically or practically necessary.

What signals to track for ongoing financial performance?

For business and investment monitoring, the leading indicators for ARICEPT ODT-like products are:

• Formulary status changes across major PBMs
• Utilization mix between ODT and tablet within donepezil
• Prescription share trends in Alzheimer’s symptomatic classes
• Gross to net movement, driven by rebate adjustments and payer contracting
• Channel shift in dispensing patterns (retail vs mail order)

Regulatory and labeling references remain stable, but payer behavior and dispensing mix drive quarter-to-quarter changes. FDA reference records provide baseline product identity and labeling context. (FDA Orange Book; DailyMed) [1][2]

Key patent and exclusivity constraints that affect the category’s economics

The Orange Book lists patents associated with reference listed drugs and can be used to map the time window when branded exclusivity or patent barriers were historically stronger. Once those constraints fall away, the class typically experiences:

• entry of generics,
• intensified payer negotiation,
• and conversion toward cost-minimizing alternatives.

This is the central reason formulation-level differentiation often has a narrower long-run financial upside compared with first-in-class or mechanism innovations. (FDA Orange Book) [1]

How does ARICEPT ODT’s “ODT convenience” monetize in the presence of generic tablets?

ODT monetization depends on payers recognizing incremental value in adherence and swallowing feasibility. In practice, that value is capped by:

• the fraction of patients who qualify for ODT due to swallowing or administration constraints,
• clinician prescribing habits after generic availability,
• and payer reimbursement thresholds for higher-cost formulations.

The product’s financial trajectory therefore tends to look like:

• share retention within a convenience-constrained subpopulation,
• offset by continued share loss where payers steer toward generic tablets.

What is the financial outlook direction implied by category structure?

The category structure is mature. The likely direction for ARICEPT ODT is:

• slow growth to decline rather than expansion, unless an unexpected payer or clinical differentiation event changes market access.
• continued reliance on incremental uptake within a convenience-sensitive patient subset.
• ongoing net sales pressure from generic competition and payer contracting leverage.

Bottom-line market dynamic summary

ARICEPT ODT sits in a mature Alzheimer’s symptomatic market where differentiation is primarily formulation convenience. The core financial driver is net price and formulary access under generic competition dynamics, moderated by the willingness of payers to pay for ODT in patients with administration constraints.

---

Key Takeaways

• ARICEPT ODT is a donepezil orally disintegrating tablet that competes on convenience and administration feasibility, not new clinical mechanism.
• Its financial trajectory is governed by generic donepezil economics, including net price pressure and formulary steering toward lower-cost tablet generics.
• ODT can preserve a narrower share segment where swallowing or adherence constraints make ODT materially preferable.
• Ongoing performance depends on payer/PBM formulary status and ODT vs tablet mix, not changes in regulatory status for the base molecule.

FAQs

1. Is ARICEPT ODT a separate molecule from donepezil?
   No. It is a formulation of donepezil hydrochloride in orally disintegrating tablet form.

2. What usually limits long-run growth for ODT variants in mature drug classes?
   Generic tablet substitution and payer cost minimization, which cap the incremental value payers will reimburse.

3. What are the main drivers of net sales for ARICEPT ODT?
   Net price after rebates and payer contracting, formulary placement, and patient switching within donepezil (ODT vs tablet).

4. Where can market participants verify regulatory and patent context for ARICEPT ODT?
   FDA’s Orange Book and FDA-linked labeling references. (FDA Orange Book; DailyMed) [1][2]

5. Does ODT convenience translate into broad market expansion in the presence of generics?
   Typically it does not create category-wide expansion; it maintains a convenience-sensitive share segment.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Drug Products (Orange Book): Donepezil hydrochloride and related entries. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Food and Drug Administration. (n.d.). DailyMed: Aricept ODT (donepezil hydrochloride) prescribing information/label. National Library of Medicine. https://dailymed.nlm.nih.gov/